The firm increased its portfolio allocation in GSK by 13.25% over the last quarter. GSK Background Information (This description is provided by the company.) GSK is a science-led global healthcare ...

The boss of GlaxoSmithKline faces one of the biggest ... who comes from a consumer healthcare background, is the right person to lead a drug and vaccine business. As one investor told the BBC ...

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the ...

GlaxoSmithKline chief executive Emma Walmsley ... experience" – which may be an oblique reference to Walmsley's background in consumer health. According to the latter, shareholders "still ...

Learn More Pharmaceutical giant GSK is pushing the boundaries of what generative AI can achieve in healthcare areas like scientific literature review, genomic analysis and drug discovery.

GSK’s vaccine portfolio. GSK’s portfolio of more than 20 marketed vaccines, one of the industry’s broadest, protects people against diseases such as meningitis, shingles, polio, measles ...

Before taking over the top job from Sir Andrew Witty last April, Walmsley was head of GSK’s consumer business. But despite this background, Walmsley said that the company’s pharmaceuticals ...

And for its part, GSK won't concede that Sirtris' small molecules don't bind the targets. In an e-mailed statement, Ad Rawcliffe, head of GSK's WorldWide Business Development group, says ...

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £14.40. The company’s shares closed today ...